Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. It offers selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company was founded by Su-Jin Lee on July 24, 2009 and is headquartered in Yongin, South Korea.